JPMorgan Chase & Co. Trims UiPath (NYSE:PATH) Target Price to $19.00

UiPath (NYSE:PATHFree Report) had its target price decreased by JPMorgan Chase & Co. from $28.00 to $19.00 in a report issued on Thursday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the healthcare company’s stock.

Several other equities research analysts have also commented on the company. DA Davidson boosted their price target on UiPath from $20.00 to $24.00 and gave the stock a neutral rating in a research note on Thursday, March 14th. Needham & Company LLC reissued a hold rating on shares of UiPath in a research note on Thursday. Mizuho decreased their price target on UiPath from $25.00 to $14.00 and set a neutral rating on the stock in a research note on Thursday. TD Cowen reissued a hold rating and set a $17.00 price target (down previously from $28.00) on shares of UiPath in a research note on Thursday. Finally, Evercore ISI decreased their price target on UiPath from $27.00 to $13.00 and set an in-line rating on the stock in a research note on Thursday. Fifteen analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, UiPath presently has an average rating of Hold and an average target price of $19.59.

Read Our Latest Report on PATH

UiPath Stock Up 1.6 %

Shares of PATH opened at $12.26 on Thursday. UiPath has a twelve month low of $11.71 and a twelve month high of $27.87. The stock’s 50 day moving average is $19.92 and its two-hundred day moving average is $22.06.

UiPath (NYSE:PATHGet Free Report) last announced its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.10. UiPath had a negative return on equity of 2.99% and a negative net margin of 6.41%. The company had revenue of $405.25 million for the quarter, compared to analyst estimates of $383.32 million. As a group, analysts anticipate that UiPath will post -0.04 earnings per share for the current fiscal year.

Insider Transactions at UiPath

In other news, CFO Ashim Gupta sold 40,000 shares of the company’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $21.66, for a total transaction of $866,400.00. Following the completion of the sale, the chief financial officer now directly owns 660,762 shares in the company, valued at approximately $14,312,104.92. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 96,000 shares of company stock worth $2,023,440 in the last ninety days. Insiders own 22.37% of the company’s stock.

Institutional Trading of UiPath

A number of institutional investors have recently added to or reduced their stakes in the business. Intech Investment Management LLC boosted its position in UiPath by 3.1% during the 4th quarter. Intech Investment Management LLC now owns 14,324 shares of the healthcare company’s stock worth $356,000 after purchasing an additional 426 shares during the period. 180 Wealth Advisors LLC boosted its position in UiPath by 0.3% during the 4th quarter. 180 Wealth Advisors LLC now owns 188,950 shares of the healthcare company’s stock worth $4,497,000 after purchasing an additional 492 shares during the period. Global Financial Private Client LLC boosted its position in UiPath by 9.3% in the 1st quarter. Global Financial Private Client LLC now owns 6,471 shares of the healthcare company’s stock valued at $144,000 after buying an additional 551 shares during the last quarter. Bleakley Financial Group LLC boosted its position in UiPath by 4.9% in the 4th quarter. Bleakley Financial Group LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after buying an additional 598 shares during the last quarter. Finally, Simplicity Solutions LLC boosted its position in UiPath by 4.9% in the 4th quarter. Simplicity Solutions LLC now owns 12,691 shares of the healthcare company’s stock valued at $315,000 after buying an additional 598 shares during the last quarter. 62.50% of the stock is owned by hedge funds and other institutional investors.

About UiPath

(Get Free Report)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

Featured Stories

Analyst Recommendations for UiPath (NYSE:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.